Rintodestrant

DB21472InvestigationalSmall molecule

Rintodestrant is a small molecule drug. Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).... Rintodestrant has a monoisotopic molecular weight of 462.09 Da.

Mechanism: Pharmacologically active on Estrogen receptor
Curator reviewed
Formula / weight: C₂₆H₁₉FO₅S · 462.49 g/mol (avg)
Code names: G1T-48 · GIT-48 · XR5-28

Resolves to

Compound

UNIIW3Y784Y0ESCAS2088518-51-6ChEMBLCHEMBL4059888

Structure

InChIKeyKOAITBOFZOEDOC-BJMVGYQFSA-NSMILESCC1=CC(F)=CC(C)=C1C(=O)C1=C(OC2=CC=C(\C=C\C(O)=O)C=C2)C2=CC=C(O)C=C2S1

Targets

P03372ESR1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rintodestrant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account